Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of⦠read more
Healthcare
Biotechnology
1 years
USD
Exclusive to Premium users
$66.90
Price+2.70%
$1.76
$2.181b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$49.376m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.54
-
1y CAGR-
3y CAGR-
5y CAGR$158.070m
$164.201m
Assets$6.131m
Liabilities-
Debt0.00%
-
Debt to EBITDA$0.00
-
1y CAGR-
3y CAGR-
5y CAGR